Clinical efficacy and safety of fondaparinux in the prevention and treatment of venous and arterial thrombosis

被引：2

作者：

Decousus, Herve ^{[1
,2
,3
]}

Rivron-Guillot, Karine ^{[1
,2
,3
]}

Girard, Gaelle ^{[3
]}

Moulin, Nathalie ^{[3
]}

机构：

[1] INSERM, CIE3, F-42055 St Etienne, France

[2] Univ St Etienne, Grp Rech Thrombose, EA3065, F-42023 St Etienne, France

[3] CHU St Etienne, Serv Med Interne & Therapeut, F-42055 St Etienne, France

来源：

FUTURE CARDIOLOGY | 2005年 / 1卷 / 06期

关键词：

acute coronary syndromes; anticoagulant; antithrombotic; arterial thrombosis; clinical trials; Factor Xa; fondaparinux; heparin; low-molecular-weight heparin; prevention; treatment; venous; thromboembolism;

D O I：

10.2217/14796678.1.6.743

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fondaparinux (Arixtra (R)) is a synthetic, selective Factor Xa inhibitor. Its pharmacokinetic profile allows once-daily subcutaneous administration of the drug without any laboratory monitoring. The benefit-to-risk ratio of fondaparinux in the prevention of venous thromboembolism has been extensively studied in both surgical and acutely ill medical patients at risk of thrombosis. Its efficacy and safety have also been investigated in the initial treatment of symptomatic deep-vein thrombosis and pulmonary embolism. Finally, a number of Phase II trials investigated the safety and efficacy of fondaparinux in patients with acute coronary syndromes, and a large Phase III program is ongoing in this setting. This review focuses on the use of fondaparinux in the prevention and treatment of thromboembolic disorders.

引用

页码：743 / 758

页数：16

共 65 条

[1] Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery [J].

Agnelli, G ;

Bergqvist, D ;

Cohen, AT ;

Gallus, AS ;

Gent, M .

BRITISH JOURNAL OF SURGERY, 2005, 92 (10) :1212-1220

[2] Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies [J].

Ahmad, S ;

Jeske, WP ;

Walenga, JM ;

Hoppensteadt, DA ;

Wood, JJ ;

Herbert, JM ;

Messmore, HL ;

Fareed, J .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (04) :259-266

[3] Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].

Amiral, J ;

Lormeau, JC ;

MarfaingKoka, A ;

Vissac, AM ;

Wolf, M ;

BoyerNeumann, C ;

Tardy, B ;

Herbert, JM ;

Meyer, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117

[4]

[Anonymous], 2000, EUROPEAN AGENCY EVAL

[5] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[6] Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].

Bauer, KA ;

Eriksson, BI ;

Lassen, MR ;

Turpie, AGG .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310

[7]

BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P397

[8]

Bergqvist D, 1997, BRIT J SURG, V84, P1099

[9] Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers [J].

Bijsterveld, NR ;

Moons, AH ;

Boekholdt, SM ;

van Aken, BE ;

Fennema, H ;

Peters, RJG ;

Meijers, JCM ;

Büller, HR ;

Levi, M .

CIRCULATION, 2002, 106 (20) :2550-2554

[10]

Buller HR, 2000, CIRCULATION, V102, P2726

← 1 2 3 4 5 6 7 →